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Summary of article’s main point: Diabetes is common among HIV/AIDS patients, 
especially within the first year of antiretroviral therapy. Newly occurring diabetes was 
associated with a high body mass index, and excessive weight gain should be avoided.  
 
Abstract 
 
Background: HIV infection and the use of anti-retroviral therapy (ART) may increase the 
risk of type 2 diabetes mellitus (T2DM). However, data from regions with a high burden of 
HIV/AIDS is limited. We determined the prevalence of T2DM at the time of presentation to a 
large HIV Clinic in Nigeria, as well as the incidence of diabetes 12 months following ART 
initiation.  
Methods: Data from patients enrolled for ART from 2011 to 2013 was analyzed, including 
2632 patients on enrollment and 2452 re-evaluated after 12 months of ART commencement. 
The presence of diabetes, demographic, clinical and biochemical data were retrieved from 
standardized databases. CD4+, HIV viral load, and hepatitis C virus (HCV) status were 
noted. Bivariate and logistic regressions were used to identify risk factors for T2DM. 
Results: Baseline T2DM prevalence was 2.3% (95%CI: 1.8% – 2.9%), and age, but not 
body mass index (BMI) was a risk factor for diabetes. After 12 months of ART, a further 
5.3% had developed T2DM. Newly developed diabetes was not associated with age, but 
was associated with BMI. There were no significant associations between prevalent or 
incident diabetes and CD4+, viral load or type of ART.  
Conclusions: Diabetes is not uncommon in HIV infected individuals at the time of 
presentation to HIV services.  Patients initiating ART then have a high risk of developing 
diabetes in the first year of ART. Incident diabetes was associated with a BMI ≥ 25.0, and 
excessive weight gain should be avoided.  
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INTRODUCTION 
 
Diabetes is a major public health concern worldwide and is rapidly increasing in sub-Sahara 
Africa, where it is projected to affect more than 20 million people by 2030. [1, 2] In Nigeria 
alone, diabetes affects between 0.6% to 11.0% of the population and is an increasing public 
health problem [3]. With its significant complication burden, diabetes presents a major 
burden to patients, their families, and health care systems.   
Nigeria also has the second largest number of individuals with the Human Immunodeficiency 
Virus (HIV) in the African continent, with more than 3 million people living with HIV/AIDS 
(PLWHA) and 600,000 receiving antiretroviral therapy (ART)[4].  PLWHA nowadays have 
longer survival with the expanding access to ART, and the prevalence of HIV/diabetes co-
morbidity is increasing.  Despite its potential public health consequences, large studies on 
the relationship between HIV/AIDS and diabetes are still uncommon.  
HIV [5-7], ART [8-10] and hepatitis C virus (HCV) [8, 10]  have been implicated as risk 
factors for diabetes. HIV causes insulin resistance and dyslipidaemia [11] and HCV is 
associated with intra-hepatic elevation of TNF-ᾳ levels, insulin resistance  and liver disease 
[12].  Although initial studies associated the onset of diabetes in PLWHA to ART containing 
protease inhibitors (PIs)[13, 14], which cause hyperglycaemia by preventing the uptake and 
metabolism of glucose and lipids by adipocytes and hepatocytes [15], subsequently pointed 
towards the nucleoside (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) by virtues of their mitochondrial toxicity and apoptosis of adipocytes [9, 16].  
However, recent studies have suggested that traditional risk factors for diabetes such as age 
and body weight are the major predictors of the development of type-2 diabetes mellitus 
(T2DM), as opposed to medications [6]. 
We have therefore determined the prevalence of T2DM in ART naïve patients at the time of 
enrolment into a cohort of newly diagnosed PLWHA, and describe the proportion of patients 
 at Liverpool School of Tropical M
edicine on June 17, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
4 
who developed T2DM within one year of ART initiation in a large HIV/AIDS cohort in Jos, 
Nigeria.  
 
METHODS 
This was a cross sectional survey of all newly registered patients attending the Prevention 
Initiative of Nigeria (APIN) adult ART clinic of Jos University Teaching Hospital (JUTH). The 
APIN clinic is a regional referral centre that provides comprehensive HIV/AIDS services for 
Plateau State in north central Nigeria, with about 3 million population. Upon registration, all 
patients undergo an induction that includes life style advice, clinical and laboratory 
investigations and assessment of ART eligibility. Patients are then followed fortnightly, 
monthly, quarterly and 6 monthly depending on whether they have symptoms or have 
initiated ART. Socio-demographic, clinical and laboratory information is entered into 
standardized forms and uploaded onto a single electronic database developed in FileMaker 
Pro (Version 10) in computers to ensure data consistency and completeness. The database 
is cleaned and curated using routine data management training and quality checks. Data 
errors for the study were further corrected by checking the original patient case notes and 
the electronic databases. 
Data on all patients ≥ 18 years old registered for treatment, care and support were retrieved 
from the database to generate a retrospective cohort of patients initiating ART from the 1st 
January 2011 to the 31st December 2013. Patients without baseline plasma glucose records 
and those who had already initiated ART at the time of enrolment were excluded from the 
analysis of baseline diabetes. The precision for estimates was ≈ ±1% based on 2632 
patients who met the selection criteria and an assumed prevalence of diabetes of 3% in 
Jos.[17] This post-hoc precision was calculated using a standard formula.[18]   
Data retrieved included age, gender, body mass index (BMI), total cholesterol (mmol/l), 
CD4+ cell counts (per µl), HIV viral load (copies/ml), ART regimen and the presence of 
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diabetes. ART was categorized as 1st or 2nd line. The most frequently prescribed 1st line 
regimens were: lamivudine + zidovudine + nevirapine (45.9%), and lamivudine or 
emtricitabine + tenofovir + efavirenz (31.4%). The most readily available 1st line regimen was 
Nevirapine-containing ART. The 2nd line ART contained atazanavir/ritonavir (92%) and 
lopinavir/ritonavir (8%). Nevirapine-containing ART was generally avoided in patients with 
liver disease or was switched to Efavirenz in those who develop hypersensitivity reactions 
(hepatotoxicity or skin rash). Efavirenz was also preferred in patients with tuberculosis. 
However, Efavirenz was avoided in individuals with severe mental health issues or in women 
of child bearing age, except if given with contraception. Second line regimens were 
considered if there was suspicion of transmitted resistance (e.g. newly infected contacts of 
PLWHIV with known ART-resistance), a diagnosis of tuberculosis (since Rifabutin was not 
readily available), Karposi sarcoma or adverse effects to the 1st line regimens. In our clinic, a 
switch to 2nd line due to treatment failure is generally considered after 12 months of ART and 
therefore not a reason for use in this study. 
Diabetes was defined as a random plasma glucose of ≥ 11.1 mmol/l, fasting plasma glucose 
of ≥ 7.0 mmol/l; or self-reported use of hypoglycaemic agents [19]. Plasma glucose 
measurements were repeated if classic osmotic symptoms were not present, to confirm the 
presence of diabetes. Pregnant women were not included in the database used for this study 
as pregnant women were monitored in a separate service. Hypercholesterolemia was 
defined according to the USA National Cholesterol Education Programme [20]. The 
estimated glomerular filtration rate (eGFR) was derived by the Cockcrof-Gault formula [21].  
A Cobas C311 auto analyser was used for plasma chemistry and HCV antibodies were 
documented by an ELISA method.  
The main outcomes were the proportion of ART naive participants with T2DM at the time of 
enrolment and the incidence of T2DM among patients without diabetes on enrolment 12 
months after initiation of ART.  
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Ethical approval was obtained from the Liverpool School of Tropical Medicine (LSTM) and 
the JUTH Ethics committees. The identity of all patients was anonymized across the data set 
by replacing their names with initials and serial numbers.  
Statistical analysis was conducted using SPSS (Chicago, IL, USA, 2011). Continuous 
variables were expressed as means ± standard deviations, or medians with ranges. 
Categorical variables were presented as proportions and compared using Chi Squared tests.  
Means were compared using unpaired Student’s t tests. Positively skewed data were log10 
transformed. Bivariate analysis was conducted and variables with p<0.25 were entered into 
multiple logistic regression models. Results of the bivariate analyses and logistic regressions 
were presented as odds ratios (OR) and adjusted odds ratios (AOR), with 95% confidence 
intervals (CI), respectively. A p-value of <0.05 was considered statistically significant.  
RESULTS 
A total of 2,753 patients were recruited in the study period.  Of these, 2632 (96%) had the 
information required to assess the presence of diabetes at baseline and 93% (2452/2632) 
for new onset diabetes one year after initiation of ART, as shown in Figure 1. The baseline 
characteristics of the overall cohort are shown in Table 1. 
A total of 61 out of 2632 patients (2.3%; 95%CI 1.8%– 2.9%) had T2DM on enrolment. Of 
these, 21 (41%) were unaware of the diagnosis. Patients with T2DM were older and had 
significantly lower eGFR than patients without T2DM, as shown in Table 2. There was no 
difference in the gender distribution, BMI, cholesterol levels, CD4+ count, HIV viral load or 
HCV positive status.  Patients > 40 years were 3.5 times more likely to have T2DM (AOR 
3.5, 95% CI 1.9 – 6.5, p < 0.001), and patients with T2DM were more likely to have reduced 
eGFR (AOR 0.99, 95% CI 0.97 – 0.98, p <0.017).  
Of the 2452 patients without T2DM on enrolment, 130 (5.3%; 95% CI: 4.2 – 6.3%) 
developed T2DM within one year of initiating ART. If these patients are added to those 
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already identified on enrolment, 191 (7.6%) of the participants had T2DM one year after 
initiating ART.   
Patients who developed T2DM after initiation of ART had higher BMI and were more likely to 
have HCV antibodies on enrolment (12.1% and 3.6% of the patients with and without 
incident T2DM, p< 0.001). There were no differences in age, gender, cholesterol 
concentrations, CD4+ count, HIV viral load, eGFR or the use of 1st or 2nd line ART among 
patients with and without incident T2DM, as shown in Table 3.   
Variables included in the logistic regression model were BMI, cholesterol ≥ 5.2 mmol/L, 
CD4+ cells/ml, viral load, eGFR and the presence of HCV antibodies. Of these, only BMI 
≥25 Kg/m2 (AOR: 7.5, 95%CI 2.9 – 23.7, p < 0.001) was independently associated with 
incident T2DM, as shown in Table 3.    
 
DISCUSSION 
Our study of a large cohort of HIV-positive Nigerians enrolled for ART showed a baseline 
diabetes prevalence of 2.3%. This was associated positively with age and inversely with 
renal function but surprisingly not with BMI. After 12 months of ART, a further 5.3% had 
developed T2DM. In this group, diabetes was not associated with age, but was positively 
associated with BMI and the presence of HCV antibodies on enrolment. Of these, only BMI > 
25 kg/m2 was independently associated with newly developed T2DM in multivariate analysis.  
The baseline T2DM prevalence is similar to other reports in both ART naïve and 
experienced patients.[6] ,[22]  However in Italy, investigators reported a higher prevalence of 
4.1% among ART experienced patients [5] and in China 10.5% of ART naïve patients had 
T2DM [7]. Patients in Italy were older (46 vs 37 years) and had a significantly higher CD4 
counts than patients in our study (CD4+ counts of 538 vs 206 cells/ul), while the prevalence 
of diabetes in a Chinese population [23] was higher than in Nigeria; suggesting that 
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prevalence of T2DM diabetes may vary with the overall T2DM prevalence in the general 
population, HIV disease progression, and the disease stage when patients access ART.  
Similarly, our 5.3% incidence of T2DM among patients on ART is similar to the 6.0% 
reported in the USA [23], but lower than a 7.2% 3-year cumulative incidence among 
recipients of early generation PIs [24]. T2DM development is a progressive condition that 
may require several years to become established among PLWHA, and a longer term follow 
up may be needed to establish total cumulative risk.    
The association of age with baseline diabetes in HIV cohorts was reported by Mehta et al 
[25] who calculated an AOR of 3.5 among patients ≥ 50 years old, and by Brar et al (6) who 
estimated an AOR of 3.0 for every 10-year age increment. The lack of association between 
age and incident diabetes after ART initiation was also reported by Yoon et al [26].  
However, others have reported that there are associations between age and incident 
diabetes in French and multinational cohorts [8, 9]  These varying findings may be due to 
differences in study design, and in the duration and type of ART used across studies. 
In our study, patients with T2DM on enrolment were more likely to have a lower eGFR, while 
there was no association with incident diabetes. It is possible that those with diabetes at 
baseline had had the disease for sufficiently long duration to affect kidney function, unlike 
incident cases who had developed diabetes within less than one year. Although older age, 
lower CD4+ and higher BMI may reduce eGFR in HIV/AIDS, data on the relationship 
between eGFR and diabetes in HIV infected people are scarce. We did not have data on the 
duration of diabetes before enrolment, but Madapalli et al [27] demonstrated a greater 
probability for progression to chronic kidney disease in patients with HIV infection and 
diabetes, compared with HIV infection alone, in a large cohort followed over a 5-year period.  
 The association between HCV and T2DM has been reported previously [6, 25]. 
Nevertheless, not all studies have reported this association, as a large Swiss HIV cohort 
study reported that HCV did not increase the risk of diabetes [10].  The presence of HCV 
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antibodies is not synonymous with active infection, and further studies are needed to 
evaluate whether recent or current infection increases the risk of diabetes.  
Unexpectedly, BMI was not associated with baseline diabetes, in contrast with other series 
[5, 6], but it was associated with newly developed diabetes on ART, as previously reported 
[8, 9].  The weight loss which may occur with uncontrolled diabetes may be responsible for 
this lack of association, as 41% of patients were unaware of their T2DM diagnosis.  Also, 
other common HIV-related illnesses causing weight loss (such as diarrhoea and 
tuberculosis) might have masked the association at baseline, and these illnesses were likely 
to be common in our cohort due to the low CD4 counts of patients on enrolment.  
Markers of HIV progression (CD4+ and viral load) did not differ between patients with and 
without T2DM and incident diabetes, which is in agreement with a previous finding in the 
USA [6].  The association of CD4+ and viral load with diabetes can be complex, and were 
not identified in the comparison of a large cohort of HIV-infected and HIV-negative veterans 
[28].  However Shen et al had reported a significant increase in diabetes risk for every 150 
CD4+ cell/ul reductions among ART naïve patients [7].  
We did not find associations between the type of ART regimen and diabetes, as reported by 
Ledergerber et al [10].   De Wit et al reported that although PIs were not associated with 
diabetes, there was an association with NRTIs [9]; with stavudine followed by zidovudine, 
and didanosine conferring the greatest risk.  In our study, the overall number of individuals 
on 2nd line ART was small and the majority were on atazanavir based PI which does not 
have significant effect on glucose metabolism. In addition, ART adherence and the use of 
medications with adverse glycaemic effects were not assessed, and none of the patients 
received stavudine or didanosine. 
Our study has strengths, but also some important limitations. It is probably the largest study 
providing concurrent data on both baseline and new diabetes on ART in HIV/AIDS patients 
residing in sub-Sahara Africa. However, our cohort had a relatively short follow up period of 
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only one year, and a longer period of observation would likely reveal further patients 
developing diabetes, and possibly stronger risk associations. Furthermore, information, such 
as waist/hip circumference of patients was not routinely measured in the clinic and metabolic 
markers were coded into dichotomous variables (e.g. diabetes yes/no), precluding further 
stratification for analysis of data.  Also, the study lacks a control cohort of non-HIV infected 
population and data of PLWHA who did not initiate ART. Lastly, the absence of data on pre-
diabetes could represent a missed opportunity to estimate and plan diabetes prevention 
initiatives. 
In conclusion, diabetes is common among HIV/AIDS patients on established ART. 
Traditional risk factors are important, and a higher BMI appears to confer the strongest risk. 
Body weight is modifiable, and supporting patients to achieve healthy dietary and lifestyle 
behaviour is important, as PLWHA may over compensate in weight gain to avoid the stigma 
associated with weight loss. The relationship between diabetes and ART needs further long 
term exploration.  Patients with HIV initiating ART need to be aware of the risk of developing 
diabetes, and services should provide integrated services for HIV/AIDS and non-
communicable diseases (NCDs) such as diabetes. 
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Table 1. The overall characteristics of the 2632 individuals enrolled in the cohort 
Variables                                                                                                 N
Age   
Mean (SD) in years      37.4±9.7 
Median [range] 36 [19-79] 
Proportion > years old 958 (36.4%) 
Male/Female (male%)    924/1708 (35.1%) 
Mean (SD) BMI 22.9 (4.8) 
Total Cholesterol (SD) mmol/l 4.1 (1.3) 
Median [range] CD4+ cells/mm3 190 [2-1837] 
Geometrical mean viral load (SD) copies/ml*1 4.3 (0.9) 
Mean eGFR (SD) ml/min*2 79.6 (24.8) 
HCV antibody present (%)*3 69/1645 (41.9%) 
ART regimens *4  
3TC+AZT+NVP 1125 (45.9%) 
3TC or FTC + TDF + EFV 769 (31.4%) 
3TC+NVP+TDF 281 (11.6%) 
3TC+AZT+EFV 59 (2.1%) 
ATZ/RTV based PI 64 (2.5%) 
LPV/RTV based PI 4 (0.3%) 
Others                                                                                                                                              150 (6.2%) 
 
Abbreviations: ART; anti-retroviral therapy, ABC; abacavir, ATZ; antazanavir, AZT; 
zidovudine, EFV; effavirenz,   FTC; emtricitabine, NVP; nevirapine, PI; protease inhibitor, 
RTV; ritonavir SD; standard deviation, 3TC; lamivudine, TDF; tenofovir. *Only patients 
followed up for incidence diabetes were exposed. Others: AZT+FCT+TDF, 3TC+NVP+ABC, 
3TC+ABC+EFV, 3TC+AZT+TDF.   *1 N= 2140; *2 N = 2157; *3 N = 1714; *4 N = 2452.
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Table 2. Characteristics of patients with and without diabetes at baseline in a cohort of people living with HIV in Jos, Nigeria 
Characteristics With diabetes 
n = 61 (2.3%) 
Without diabetes 
n = 2571 (97.7%) 
 OR (95%CI) p-value 
Age > 40 years 43/61 (70.5%) 915/2571 (35.6%)  4.32 (2.48 – 7.54) 0.0001 
Male:Female (%male) 25:36 (41%) 899:1656 (35%)  1.29 (0.77 – 2.16) 0.330 
BMI ≥25 Kg/m2 22 (36.1%) 830 (32.3%)  1.13 (0.79 – 1.65) 0.490 
Mean Cholesterol (SD) mmol/L 4.1 (1.4) 4.1 (1.3)  1.07 (0.94 – 1.23) 0.980 
Median CD4+ cells/mm3 (range) 180 (10 - 867) 190 (2 - 1837)  1.00 (1.00 – 1.00) 0.938 
Log mean viral load (SD) 4.3 (0.9) 4.3 (0.9)  1.00 (1.00 – 1.00) 0.340 
*Mean eGFR in ml/min (SD) 67.5 (22.3) 79.9 (24.8)  0.98 (0.97 – 0.99) 0.005 
Positive HCV antibody  1/40 (2.5%) 68/1674 (4.1%)  0.61 (0.08 – 4.47) 0.619 
BMI, body mass index; CD, cluster of differentiation; SD=Standard deviation; CI, confidence interval; eGFR, estimated glomerular filtration rate, 
HCV, Hepatitis C virus; OR, odds ratio. * variables with p<0.25 in bivariate analysis. 
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Table 3. Bivariate and multivariate analysis of risk factors of new onset diabetes in a cohort of people living with HIV on antiretroviral therapy in 
Jos, Nigeria 
 
Characteristics 
 
New diabetes 
n = 130 (5.3%) 
No diabetes 
n = 2322 (94.7%) 
OR (95% CI) AOR (95%CI) p-value 
Age > 40 years 51 (39.2%) 822 (35.4%) 1.13 (0.79 – 1.61) 1.02 (0.99 – 1.05) 0.14 
*Mean Cholesterol (SD) mmol/L 4.2 (1.2) 4.1 (1.3) 1.07 (0.94 – 1.23) 0.88 (0.71 – 1.10) 0.23 
*MedianCD4+cells/mm3 (range) 206 (13 - 968) 188 (2 - 1837) 0.98 (0.90 – 1.10) 1.00 (1.00 -1.02) 0.90 
*Log mean viral load (SD) 4.5 (0.89) 4.3 (0.92) 0.91 (0.89 – 1.09) 1.21 (0.90 – 1.64) 0.21 
*Mean eGFR in ml/min (SD) 78.9 (25.3) 80.0 (24.8) 1.01 (0.99 – 1.03) 0.99 (0.99 – 1.01) 0.85 
*Positive HCV antibody 12/99 (12.1%) 56/1575 (3.6%) 1.15 (1.03 - 1.28) 2.46 (0.58 – 10.54) 0.22 
First Line ART                                                              123/130 (94.6%) 2245/2306 (97.3%) 1.16 (0.97 - 1.39) NA - 
 
AOR, adjusted odds ratio; BMI, body mass index; CD, cluster of differentiation; CI, confidence interval; eGFR, estimated glomerular filtration 
rate, HCV, Hepatitis C virus; OR, odds ratio; NA, not applicable. *variables with p<0.25 in bivariate analysis which were also baseline 
characteristics adjusted for associations with new diabetes. Hosmer and Lemeshow test: Chi Square = 9.242; p-value = 0.32 
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